Lisa Scholl, NP
Family · Nashville, TNNPI 1184867541
Payments from drug & device makers
Across 56 payments — averaging $110.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Gilead$602
- Seagen Inc.$516
- Incyte Corporation$408
- Stemline Therapeutics Inc.$330
- Puma Biotechnology, Inc.$283
- plus $2K from 14 others
What the payments were for
- Consulting fees$87014%
- Food & beverage$5,07982%
- Education$2484%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 11 | $1,912 |
| Gilead(2 entities) | 7 | $602 |
| Seagen Inc. | 5 | $516 |
| Incyte Corporation | 4 | $408 |
| Stemline Therapeutics Inc. | 3 | $330 |
| Puma Biotechnology, Inc. | 4 | $283 |
| Merck | 6 | $264 |
| Regeneron Healthcare Solutions, Inc. | 2 | $235 |
| Johnson & Johnson(2 entities) | 2 | $216 |
| GSK | 2 | $215 |
| Daiichi Sankyo Inc. | 1 | $203 |
| Amgen | 1 | $139 |
| Novo Nordisk | 1 | $125 |
| Genmab U.S., Inc. | 1 | $123 |
| Exelixis Inc. | 1 | $122 |
| Rigel Pharmaceuticals, Inc. | 1 | $117 |
| EMD Serono, Inc. | 1 | $114 |
| Beigene USA, Inc. | 1 | $108 |
| Genentech USA, Inc. | 1 | $108 |
| E.r. Squibb & Sons, L.L.C. | 1 | $58 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,197 in reported general payments places this provider in the 90th percentile of 6,706 family providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Exemestane | 75 | $15,079 |
| Letrozole | 320 | $7,726 |
| Tamoxifen Citrate | 84 | $2,395 |
| Anastrozole | 74 | $1,186 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 19 | $537 |
| Ondansetron Hcl | 19 | $173 |
| Gabapentin | 16 | $123 |
Paid to pharmacies, not to this prescriber.
Other family in Nashville
- Tamera ThoenerNashville$254K
- Jennifer WilliamsNashville$213K
- Lori LankfordNashville$148K
- Melissa RikalNashville$144K
- Nicole DelliseNashville$67K
- Lesley BallanceNashville$63K
- Jeffrey WoodsNashville$38K
- Courtney HavillNashville$35K
- Collette UtleyNashville$28K
- Stacy BrownMt Juliet$719K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.